Candel Therapeutics, Inc. (NASDAQ: CADL) shares fell about 39% to $5.11 in after-hours trading Thursday. The cancer immunotherapy develoCandel Therapeutics prostate cancerper said it now…
November 13, 2026
November 10, 2026
PepGen Stock More Than Doubles as FREEDOM2-DM1 Data Show Record Splicing Correction
PepGen Inc. (NASDAQ: PEPG) shares more than doubled in premarket trading Tuesday, jumping 136.4% to $5.65 from Monday’s close of $2.39. The surge came after…
Ocular Therapeutix (NASDAQ: OCUL) said it remains on track to file its FDA approval application for Axpaxli in wet age-related macular degeneration (wet AMD) this…
November 02, 2026
uniQure’s Huntington’s Gene Therapy Wins FDA Acceptance and Priority Review, Setting Up a May 2027 Decision
uniQure N.V. (NASDAQ: QURE) cleared a major regulatory hurdle on Monday. The FDA accepted for review the company’s Biologics License Application (BLA) for ifezuntirgene inilparvovec…
October 27, 2026
Oncolytics Says Every Responder Survived Past One Year in Anal Cancer Study, Sets Sights on HPV-Driven Head and Neck Cancer
Oncolytics Biotech® Inc. (Nasdaq: ONCY) today released updated durability and survival data showing that every patient who responded to its pelareorep combination in previously treated…
Telix Pharmaceuticals Limited (NASDAQ: TLX) reported third-quarter revenue of $245 million, up 19% from a year earlier, and launched its new Pixclara brain cancer imaging…
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) shares rose about 21% to roughly $1.37 by mid-day Monday, up from Friday’s $1.13 close. The rally came as Actinium…
October 19, 2026
Merck KGaA to Buy Silence Therapeutics for $1.3 Billion, More Than Doubling the Stock
Silence Therapeutics plc (NASDAQ: SLN) shares more than doubled Monday morning after Germany’s Merck KGaA agreed to acquire the London-based RNA drug developer for $20…
October 16, 2026
Fractyl’s Revita Meets Its Six-Month Pivotal Goal, but Shares Sink as Investors Weigh the Margin
Fractyl Health, Inc. (NASDAQ: GUTS) said Friday morning that its Revita procedure met the six-month co-primary endpoint of the pivotal REMAIN-1 study. Patients who received…
October 14, 2026
Verastem Jumps as VS-7375 Posts 50% Response Rate in Pancreatic Cancer, Backed by $250 Million Raise and CEO Succession Plan
Verastem, Inc. (NASDAQ: VSTM) shares rose about 19% on Wednesday, putting the stock at the top of the PRISM Women’s Health Index. The jump followed…
October 14, 2026
Aquestive Hands U.S. Rights to LIBERVANT to Eton as It Prepares for an April 2027 Launch
Aquestive Therapeutics (NASDAQ: AQST) has signed an exclusive U.S. licensing and supply agreement with Eton Pharmaceuticals (NASDAQ: ETON) for LIBERVANT® (diazepam) buccal film. LIBERVANT is…
October 08, 2026
bioAffinity Shares Surge 31% as CyPath Lung Sales Double and Japan Allows a New Patent
bioAffinity Technologies, Inc. (NASDAQ: BIAF) shares jumped 31.33% to $8.09 by mid-day Thursday, a gain of $1.93 from Wednesday’s $6.16 close. Trading volume reached nearly…